Cargando…
Re: Efficacy of favipiravir in adults with mild COVID-19 by Bosaeed et al.
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9087153/ https://www.ncbi.nlm.nih.gov/pubmed/35562086 http://dx.doi.org/10.1016/j.cmi.2022.04.024 |
| _version_ | 1784704140471959552 |
|---|---|
| author | Mori, Nobuaki |
| author_facet | Mori, Nobuaki |
| author_sort | Mori, Nobuaki |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9087153 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-90871532022-05-10 Re: Efficacy of favipiravir in adults with mild COVID-19 by Bosaeed et al. Mori, Nobuaki Clin Microbiol Infect Letter to the Editor European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. 2022-10 2022-05-10 /pmc/articles/PMC9087153/ /pubmed/35562086 http://dx.doi.org/10.1016/j.cmi.2022.04.024 Text en © 2022 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | Letter to the Editor Mori, Nobuaki Re: Efficacy of favipiravir in adults with mild COVID-19 by Bosaeed et al. |
| title | Re: Efficacy of favipiravir in adults with mild COVID-19 by Bosaeed et al. |
| title_full | Re: Efficacy of favipiravir in adults with mild COVID-19 by Bosaeed et al. |
| title_fullStr | Re: Efficacy of favipiravir in adults with mild COVID-19 by Bosaeed et al. |
| title_full_unstemmed | Re: Efficacy of favipiravir in adults with mild COVID-19 by Bosaeed et al. |
| title_short | Re: Efficacy of favipiravir in adults with mild COVID-19 by Bosaeed et al. |
| title_sort | re: efficacy of favipiravir in adults with mild covid-19 by bosaeed et al. |
| topic | Letter to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9087153/ https://www.ncbi.nlm.nih.gov/pubmed/35562086 http://dx.doi.org/10.1016/j.cmi.2022.04.024 |
| work_keys_str_mv | AT morinobuaki reefficacyoffavipiravirinadultswithmildcovid19bybosaeedetal |